Clear Labs

Pixelgen Technologies Appoints Mostafa Ronaghi to Scientific Advisory Board

Retrieved on: 
Tuesday, April 30, 2024
Stanford University, Membrane, Karolinska Institute, Genomics, Mostafa Ronaghi, Pyrosequencing, Pixelation, Clear Labs, Proteome, Imperial College London, Culture, GRAIL, Drug development, Management

STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.

Key Points: 
  • STOCKHOLM, April 30, 2024 /PRNewswire/ -- Pixelgen Technologies announced today the appointment of Mostafa Ronaghi, Ph.D., to its Scientific Advisory Board.
  • "Mostafa is a recognized life sciences visionary leader, with deep expertise in genomics and a tested entrepreneurial spirit," said Pixelgen CEO Simon Fredriksson.
  • "These attributes align well with Pixelgen's mission and culture, and we are honored to have him on our board.
  • "I'm thrilled to join Pixelgen's Scientific Advisory Board and look forward to working with the company's impressive team to continue developing Molecular Pixelation," Ronaghi said.

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

Retrieved on: 
Wednesday, April 17, 2024
Research, Infectious Diseases, Neurology, Biotechnology, Other Health, Health, General Health, Other Science, Science, American Academy, GenePeeks, University, Cancer, Foundation Medicine, Genomics, DSM-IV codes, Infection, Bacteria, Fortune 500, Medical laboratory, Clear Labs, NGS, CLIA, Medicine, Encephalitis, UCSF, Ventricular septal defect, Patient, Meningitis, Parasitism, AAN, Physician, Immunodeficiency, Virus, Neuro, Fungus, CSF, Diagnosis, Neoplasm, Cerebrospinal fluid, Metagenomics, Pharmaceutical industry

The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.

Key Points: 
  • The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.
  • In addition, the study found mNGS provided a definitive diagnosis for nearly 1 in 3 immunocompromised patients.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.
  • Prior to joining Delve Bio, Mr. Field served as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina).

Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

Retrieved on: 
Thursday, April 11, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Doctor of Philosophy, Genomics, Mostafa Ronaghi, Pyrosequencing, Trauma, Clear Labs, NGS, Senior, Translation, GRAIL, SMMT, Organization, Royal institute, Management

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately.
  • “We are excited to add Dr. Ronaghi to complement our excellent group of current board members,” stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to our impressive executive team.”
    Dr. Ronaghi is the Co-Founder and Executive Board Member of Cellanome.
  • “I am very pleased at the opportunity to join Summit’s Board of Directors,” said Dr. Ronaghi.

Clear Labs Launches Microbial Surveillance Whole Genome Sequencing Solution

Retrieved on: 
Monday, May 22, 2023
A-DNA, Clear Labs, Wage, Laboratory, Workflow, Public, Infection, Clear, Consistency, Whole genome sequencing, Hospital, SAN, WGS, System, Health, Labs, Automation, Antibiotics, Vaccine, Wine

SAN CARLOS, Calif., May 22, 2023 /PRNewswire-PRWeb/ -- Clear Labs, a leader in next-generation sequencing automation workflow solutions, announces the launch of the Clear Dx™ Microbial Surveillance WGS, a fully-automated, end-to-end whole genome sequencing (WGS) solution for bacterial and fungal isolates. This groundbreaking application sets a new standard for speed, efficiency and simplicity in pathogen characterization.

Key Points: 
  • SAN CARLOS, Calif., May 22, 2023 /PRNewswire-PRWeb/ -- Clear Labs , a leader in next-generation sequencing automation workflow solutions, announces the launch of the Clear Dx™ Microbial Surveillance WGS, a fully-automated, end-to-end whole genome sequencing (WGS) solution for bacterial and fungal isolates.
  • With Clear Dx™ Microbial Surveillance WGS, Clear Labs helps labs address this challenge by providing a turnkey solution that automates the entire WGS process for up to 12 microbial isolates in just 27 hours.
  • The Nebraska Public Health Laboratory (NPHL) has been a long-term collaborator of Clear Labs on the Clear Dx™ System and was excited to help validate the new Microbial Surveillance WGS solution.
  • With this groundbreaking solution, Clear Labs continues to redefine the landscape of whole genome sequencing and empower laboratories to safeguard health more efficiently than ever before.

Clear Labs to Present at IAFP Annual Meeting of 4,000 Global Food Safety Experts

Retrieved on: 
Wednesday, July 27, 2022
Clear Labs, DNA, Whole genome sequencing, NGS, International Association for Food Protection, Genomics, SAN, Annual general meeting, Culture, IAFP, Serotype, Infection, Method, Robotics, International Association, Labs, Food safety, PCR, Vaccine, Salmonella

SAN CARLOS, Calif., July 27, 2022 /PRNewswire-PRWeb/ -- This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending and presenting at the International Association for Food Protection (IAFP) 2022 Annual Meeting. As a renowned worldwide food safety conference, the IAFP Annual Meeting educates attendees on current and emerging food safety issues, as well as the latest innovative solutions to new and recurring problems. The meeting also provides an opportunity to network with nearly 4,000 top food safety professionals from six continents.

Key Points: 
  • As a renowned worldwide food safety conference, the IAFP Annual Meeting educates attendees on current and emerging food safety issues, as well as the latest innovative solutions to new and recurring problems.
  • The meeting also provides an opportunity to network with nearly 4,000 top food safety professionals from six continents.
  • Clear Labs Staff Scientist Andrew Lin is among notable guests leading more than 100 sessions ranging from cultivating diversity in food safety spaces to innovative ways for improving the detection and serotyping of Salmonella.
  • Clear Labs is widely recognized as a pioneer in food safety.

Clear Labs to Lead Session on Whole Genome Sequencing at AACC Annual Scientific Meeting in Chicago

Retrieved on: 
Monday, July 25, 2022
Clear Labs, DNA, Association, NGS, Eyeish, Infection, Health care, Genomics, CT, Whole genome sequencing, Doctor of Philosophy, Hospital, SAN, Poster, American Association for Clinical Chemistry, American Association, WGS, Hospital-acquired infection, HAI, Automation, Technology, Virulence, AACC, Robotics, Subclinical infection, Antibiotics

SAN CARLOS, Calif., July 25, 2022 /PRNewswire-PRWeb/ -- This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending and presenting at the The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting + Clinical Lab Expo. The AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. Its annual event showcases cutting-edge research, technology and automation shaping the future of diagnostics.

Key Points: 
  • The AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare.
  • Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex workflows for clinical and applied markets.
  • By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs liberates genomics to deliver increased clarity.
  • With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.

Slone Partners Places Edward Fan as Chief Financial Officer at Clear Labs

Retrieved on: 
Tuesday, July 12, 2022
People, NGS, Precision medicine, Marketing, Biotechnology, Lazard, Genomics, CEO, J. P. Morgan, Clear Labs, Master, Robotics, Tufts University, Bachelor, CFO, Hospital, Edward Fanning, Intelligence, M&A, Initial public offering, Infection, Industry, Shire (pharmaceutical company), DNA, Pharmaceutical industry, Management, Engineering

SOUTH RIDING, Va., July 12, 2022   /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Edward Fan as Chief Financial Officer (CFO) at Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics.

Key Points: 
  • SOUTH RIDING, Va., July 12, 2022 /PRNewswire-PRWeb/ -- Slone Partners , a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Edward Fan as Chief Financial Officer (CFO) at Clear Labs , the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics.
  • Earlier in his career, Fan held operating roles at Sanofi, Werfen, and Shire Pharmaceuticals in marketing, product management, competitive intelligence, and R&D.
  • "Edward Fan is a highly respected and admired financial and operations leader with a wealth of experience across healthcare and the life sciences industry," said Slone Partners CEO Leslie Loveless .
  • "He is extremely smart, passionate, and visionary, and will be a wonderful addition to the Clear Labs leadership team."

Clear Labs Expands Leadership Team with Appointment of Edward Fan as Chief Financial Officer

Retrieved on: 
Monday, July 11, 2022
SAN, Solution, Clear Labs, CEO, Salmonella, Marketing, Labs, DNA, J. P. Morgan, Genomics, Infection, Intelligence, NGS, Edward Fanning, Shire (pharmaceutical company), Initial public offering, Food safety, Growth, J.P. Morgan in the United Kingdom, Hospital, Robotics, Lazard, Antibiotics, Listeria

SAN CARLOS, Calif., July 11, 2022 /PRNewswire-PRWeb/ -- Today, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, announced the appointment of Edward Fan as its new Chief Financial Officer to support the company's next phase of growth. Fan joins Clear Labs following a distinguished career in healthcare investment banking at J.P. Morgan and Lazard and a range of operating roles at leading healthcare companies.

Key Points: 
  • Fan joins Clear Labs following a distinguished career in healthcare investment banking at J.P. Morgan and Lazard and a range of operating roles at leading healthcare companies.
  • "We are excited for the significant growth opportunities in front of Clear Labs, and Ed's appointment underscores our commitment to bringing on the best and brightest minds in our field.
  • In addition to its clinical solutions, Clear Labs is a pioneer in food safety for Listeria and Salmonella detection through its Clear Safety platform.
  • With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.

Clear Labs to Address NGS for Near Real-Time Surveillance and Outbreak Response at ASM Microbe 2022 in Washington, D.C.

Retrieved on: 
Monday, June 6, 2022
Midnight, ASM, NGS, Data analysis, CMO, Program, COVID-19, Labs, Infection, Associate, Policy, Public health, CEO, Clear Labs, Microbiology, Solution, Robotics, Technology, DNA, Adoption, AST, CSO, Severe acute respiratory syndrome coronavirus 2, Genomics, Comparison, Medical device, Vaccine, Antibiotics, Science, Industry

SAN CARLOS, Calif., June 6, 2022 /PRNewswire-PRWeb/ -- This week, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is attending ASM Microbe. The conference aims to drive discovery, innovation and collaboration across the full spectrum of microbiology. Clear Labs Chief Scientific Officer and Chief Operating Officer Ramin Khaksar is leading a session about the value of Near Real-Time Surveillance for Outbreak Response, while CEO Sasan Amini will join Dr. Khaksar at the close of the event for the ASM Clin Micro Open 2022.

Key Points: 
  • NGS technology helped guide public health decision-making regarding the Covid-19 pandemic, and the prospects of NGS toward the response of other infectious diseases is promising.
  • Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets.
  • Clear Labs' turnkey platform accelerates outcomes and improves accuracy for detection and surveillance of infectious diseases.
  • With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.

Clear Labs Presents New Science at Association of Public Health Laboratories (APHL) Annual Conference

Retrieved on: 
Thursday, May 12, 2022
Salmonella, Severe acute respiratory syndrome coronavirus 2, Labs, COVID-19, Data analysis, DNA, NGS, Death, Informatics, Public health, APHL, Clear Labs, Infection, Gold, Solution, Environmental health, Robotics, Method, Global health, Public health surveillance, Lecture, Conference, Safety, Virulence, Technology, Genomics, Food safety, Pathogen, PHL, Vaccine, Pharmaceutical industry, Antibiotics, Listeria

SAN CARLOS, Calif., May 12, 2022 /PRNewswire-PRWeb/ -- Today, Clear Labs, the leader in fully automated, next-generation sequencing (NGS) for turnkey genomic surveillance and diagnostics, is announcing that leaders from the company will be presenting at the APHL Annual Conference, a hybrid live and virtual event for the public health laboratory (PHL) community, which brings together leaders, scientists, influencers and partners to share issues, trends and best practices driving laboratory science and public health today.

Key Points: 
  • "Clear Labs is prepared to address the increasingly significant role that NGS plays in detecting and understanding issues in the food safety and clinical diagnostic sectors.
  • Our fully automated platform is proven in both of these areas and we know the benefit we bring to supporting public health labs, particularly as sequencing has taken center stage in our post-pandemic world."
  • In addition to presenting at the APHL Conference, Clear Labs is a gold sponsor and will be showcasing its powerful approach at booth #315/317.
  • With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow's novel pathogens.